Remove Heart Valves Remove Innovation Remove Pharmacology
article thumbnail

TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker

DAIC

Tricuspid regurgitation (TR) is a common and serious disease for which open heart surgery and symptomatic pharmacologic treatment are the current standard treatment options. Owing to high mortality risk, access to open heart surgery is severely restricted and is not considered an option for most patients with TR.

article thumbnail

Top Interventional Cardiology Conferences and Courses in 2024

Cardiology Update

Fellows 2024 offers hands-on training covering revascularization, angioplasty, stents, pharmacologic therapy, and intravascular imaging/physiology. Noncoronary topics like structural heart disease and vascular medicine are also addressed. The course is relevant for the entire heart valve team.